EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans

Xue-Qing Li iD, Marie Elebring, Anders Dahlén, Lars Weidolf

Drug Metabolism and Disposition · 2023-10 · 51 (10) · 1350-1361

DOI: 10.1124/dmd.123.001370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2023-10. Verfasst von Xue-Qing Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (X.-Q.L., M.E., L.…. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Acetylgalactosamine. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 protein synthesis. It is a phosphorothioated 3-10-3 gapmer with a central DNA sequence flanked by constrained 2'-O-ethyl 2',4'-bridged nucleic acid (cEt-BNA) wings and conjugated to a triantennary N-acetylgalactosamine (GalNAc) ligand at the 5'-end. Herein we report the biotransformation of AZD8233, as given by liver, kidney, plasma and urine samples, after repeated subcutaneous administration to humans, mice, rats, rabbits, and monkeys. Metabolite profiles were characterized using liquid chromatography high-resolution mass spectrometry. Metabolite formation was consistent across species, mainly comprising hydrolysis of GalNAc sugars, phosphodiester-linker hydrolysis releasing the full-length ASO, and endonuclease-mediated hydrolysis within the central DNA gap followed by exonuclease-mediated 5'- or 3'-degradation. All metabolites contained the 5'- or 3'-cEt-BNA terminus. Most shortmer metabolites had the free terminal alcohol at 5'- and 3'-positions of ribose, although six were found retaining the terminal 5'-phosphorothioate group. GalNAc conjugated shortmer metabolites were also observed in urine. Synthesized metabolite standards were applied for (semi)quantitative metabolite assessment. Intact AZD8233 was the major component in plasma, whereas the unconjugated full-length ASO was predominant in tissues. In plasma, most metabolites were shortmers retaining the 3'-cEt-BNA terminus, whereas metabolites containing the 5'- or 3'-cEt-BNA terminus were detected in both tissues and urine. All metabolites in human plasma were also detected in all nonclinical species, and all human urine metabolites were detected in monkey urine. In general, metabolite profiles in animal species were qualitatively similar and quantitatively exceeded the exposures of the circulating metabolites in humans at the doses studied. SIGNIFICANCE STATEMENT: This study presents metabolite identification and profiling of AZD8233, an N-acetylgalactosamine-conjugated antisense oligonucleotide (ASO), across species. A biotransformation strategy for ASOs was established by utilizing biologic samples collected from toxicology and/or clinical studies and liquid chromatography high-resolution mass spectrometry analysis without conducting bespoke radiolabeled absorption, distribution, metabolism, and excretion studies. The generated biotransformation package was considered adequate by health authorities to progress AZD8233 into a phase 3 program, proving its applicability to future metabolism studies of ASOs in drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseAcetylgalactosamineHumansRatsMiceAnimalsRabbitsOligonucleotidesChromatography, LiquidMass Spectrometry

Substanzen

Oligonucleotides, AntisenseAcetylgalactosamineOligonucleotides

Autor:innen und Institutionen

  • DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (X.-Q.L., M.E., L.W.); and Oligonucleotide Discovery, Discovery Sciences, BioPharmaceuti…

ORCID-Profile: Xue-Qing Li

Zitieren

APA

Li, X. Q., Elebring, M., Dahlén, A., & Weidolf, L. (2023). In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans. Drug Metabolism and Disposition, 51(10), 1350-1361. https://doi.org/10.1124/dmd.123.001370

Vancouver

Li XQ, Elebring M, Dahlén A, Weidolf L. In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans. Drug Metabolism and Disposition. 2023;51(10):1350-1361. doi:10.1124/dmd.123.001370

BibTeX
@article{Li2023,
  author = {Li, Xue-Qing and Elebring, Marie and Dahlén, Anders and Weidolf, Lars},
  title = {In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated Antisense Oligonucleotide AZD8233 Using Liquid Chromatography High-Resolution Mass Spectrometry: A Cross-Species Comparison in Animals and Humans},
  journal = {Drug Metabolism and Disposition},
  year = {2023},
  volume = {51},
  number = {10},
  pages = {1350--1361},
  doi = {10.1124/dmd.123.001370}
}
Kostenlos starten →